Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on SAB Biotherapeutics. The associated price target remains the same with $9.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on SAB Biotherapeutics securing essential capital through a $175M private placement, which extends their cash runway into 2028. This financial boost is crucial for initiating the Phase 2b SAFEGUARD trial in the third quarter of 2025, aimed at evaluating SAB-142 for treating Stage 3 Type 1 Diabetes. The involvement of strategic investors like Sanofi and other notable firms underscores confidence in the company’s potential.
Additionally, the completion of full randomization in their Phase 1 study, including a cohort of participants with Type 1 Diabetes, provides promising data on SAB-142’s safety and efficacy. The upcoming Phase 2b trial, designed as a pivotal study, has received alignment from the FDA, further solidifying its path towards potential approval. These factors collectively contribute to a positive outlook for SAB Biotherapeutics, justifying the Buy rating.